Evolving Therapeutic Landscape in Metastatic Urothelial Carcinoma
Dr. Skelton outlines the integration of antibody-drug conjugates (ADCs) into treatment algorithms, particularly the role of enfortumab vedotin (EV) in combination with pembrolizumab, which has demonstrated efficacy in the first-line setting. This is supported by the EV-302 trial, which showed this combination significantly improves overall survival and progression-free survival compared to standard platinum-based chemotherapy, establishing it as a new standard of care.